KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Change in Intangibles (2016 - 2020)

Historic Change in Intangibles for Pfizer (PFE) over the last 8 years, with Q3 2020 value amounting to $38.0 million.

  • Pfizer's Change in Intangibles fell 6082.47% to $38.0 million in Q3 2020 from the same period last year, while for Sep 2020 it was $125.0 million, marking a year-over-year decrease of 7334.75%. This contributed to the annual value of $539.0 million for FY2020, which is 2894.74% up from last year.
  • As of Q3 2020, Pfizer's Change in Intangibles stood at $38.0 million, which was down 6082.47% from $1.0 million recorded in Q2 2020.
  • Pfizer's 5-year Change in Intangibles high stood at $158.0 million for Q1 2019, and its period low was $1.0 million during Q2 2020.
  • Over the past 5 years, Pfizer's median Change in Intangibles value was $76.5 million (recorded in 2016), while the average stood at $74.1 million.
  • Its Change in Intangibles has fluctuated over the past 5 years, first surged by 182000.0% in 2016, then tumbled by 9908.26% in 2020.
  • Over the past 5 years, Pfizer's Change in Intangibles (Quarter) stood at $80.0 million in 2016, then fell by 8.75% to $73.0 million in 2017, then soared by 43.84% to $105.0 million in 2018, then tumbled by 48.57% to $54.0 million in 2019, then fell by 29.63% to $38.0 million in 2020.
  • Its Change in Intangibles was $38.0 million in Q3 2020, compared to $1.0 million in Q2 2020 and $32.0 million in Q1 2020.